Vasculitis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Vasculitis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Vasculitis therapeutics.

Synopsis

• In 2022, there will be more than 855,000 diagnosed prevalence cases of vasculitis across 16 pharmaceutical markets.
• There are five monoclonal antibody therapies approved for the treatment of various types of vasculitis.
• The vasculitis pipeline consists of 54 pharmaceuticals spanning all stages of development, with approximately 43% of drugs in mid- to late-stage development.
• Non-commercial sponsors dominate clinical trial development in vasculitis, with the US emerging as the key countries for conducting trials in vasculitis.
• Deals involving partnerships were the most common type of deal in Asia-pacific and Europe.
• A total of 10 players are currently developing newer products for the treatment of vasculitis in the late-stage pipeline, suggesting a drastic change in the vasculitis market in the immediate future.

Scope

GlobalData’s Vasculitis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type and Route of Administration
• Product Profiles with Sales Forecast
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Vasculitis market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Vasculitis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.